CPC technology class · A61
A61M — Devices FOR Introducing Media INTO
Devices for introducing media into, or onto, the body ; devices for transducing body media or for taking media from the body ; devices for producing or ending sleep or stupor. 57,639 US utility patents granted 2015–2025, with the leading assignees and year-by-year filing trajectory.
- 57,639
- US patents granted
- A61
- Parent CPC class
- 20
- Active assignees
- +37%
- 5-yr velocity
CPC subclass A61M — DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR — covers 57,639 US utility patents granted between 2015 and 2025 according to USPTO PatentsView records. This subclass sits within the broader CPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE), one of roughly 250 top-level technology categories in the Cooperative Patent Classification system jointly maintained by the USPTO and the European Patent Office. At the subclass level, four-character codes like A61M give the most practical resolution for tracking a specific technology domain without losing sight of adjacent filings. Every grant here has been classified by a USPTO examiner based on the technical disclosure in the patent specification.
The competitive landscape in A61M is shaped by 20 distinct companies actively filing in this space. Becton, Dickinson and Company leads with 1,249 patents, followed by Sanofi-Aventis Deutschland GMBH at 1,348 grants and Boston Scientific Scimed, Inc. at 3,361. Concentration at the top of the leaderboard indicates whether this technology area is dominated by a handful of incumbents or fragmented across many filers — a useful signal for investors evaluating competitive moats and for product teams mapping freedom-to-operate risk.
Filing trajectory matters as much as static counts. The yearly series on this page plots grants from 2015 through 2025, highlighting whether innovation in A61M is accelerating, plateauing, or cooling. Technology areas with rising post-2020 activity often reflect emerging markets or new platform shifts, while declining filings can signal mature domains where incremental improvement has slowed. Researchers, licensing professionals, and competitive-intelligence teams use these patterns — together with the top-assignee distribution — to decide where to invest, where to license, and where to avoid entanglement. All counts on this page come directly from USPTO PatentsView and reflect US granted utility patents only.
Is A61M innovation accelerating?
US utility-patent grants per year in A61M, 2015–2025 — recent five years are up 37% versus 2015–2019.
Who leads A61M?
The 12 most active assignees in DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR — wider bars mean more grants
- Becton Dickinson and 2,235
Becton, Dickinson and Company
2,235 patents
- Sanofi-aventis Deutsc… 1,348
Sanofi-Aventis Deutschland GMBH
1,348 patents
- Boston Scientific Sci… 3,361
Boston Scientific Scimed, Inc.
3,361 patents
- Koniniklijke Philips
KONINIKLIJKE PHILIPS N.V.
9,647 patents
- Fisher & Paykel Healt… 1,077
Fisher & Paykel Healthcare Limited
1,077 patents
- Covidien
Covidien LP
6,485 patents
- Terumo 1,250
Terumo Kabushiki Kaisha
1,250 patents
- Resmed Pty 800
ResMed Pty Ltd
800 patents
- Medtronic 3,184
Medtronic, Inc.
3,184 patents
- Medtronic Minimed 769
MEDTRONIC MINIMED, INC.
769 patents
- Kci Licensing 673
KCI Licensing, Inc.
673 patents
- Fresenius Medical Car… 615
Fresenius Medical Care Deutschland GmbH
615 patents
What this shows Becton Dickinson and is the most active filer in A61M, holding 1,249 of the 57,639 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.
View data table
| Rank | Company | Patents in A61M |
|---|---|---|
| #1 | Becton, Dickinson and Company | 2,235 |
| #2 | Sanofi-Aventis Deutschland GMBH | 1,348 |
| #3 | Boston Scientific Scimed, Inc. | 3,361 |
| #4 | KONINIKLIJKE PHILIPS N.V. | 9,647 |
| #5 | Fisher & Paykel Healthcare Limited | 1,077 |
| #6 | Covidien LP | 6,485 |
| #7 | Terumo Kabushiki Kaisha | 1,250 |
| #8 | ResMed Pty Ltd | 800 |
| #9 | Medtronic, Inc. | 3,184 |
| #10 | MEDTRONIC MINIMED, INC. | 769 |
| #11 | KCI Licensing, Inc. | 673 |
| #12 | Fresenius Medical Care Deutschland GmbH | 615 |
| #13 | DEKA Products Limited Parternship | 1,025 |
| #14 | Fresenius Medical Care Holdings, Inc. | 520 |
| #15 | CAREFUSION 303, INC. | 711 |
| #16 | COOK MEDICAL TECHNOLOGIES LLC | 1,327 |
| #17 | Baxter International Inc. | 620 |
| #18 | Baxter Healthcare SA | 590 |
| #19 | C.R. Bard, Inc. | 808 |
| #20 | Biosense Webster (Israel) Ltd. | 1,301 |
About This Class
CPC subclass A61M belongs to class A61.
57,639 patents were granted in this class between 2015 and 2025.
20 companies actively patent in this space.
Classification System
Cooperative Patent Classification (CPC) is a hierarchical patent classification system used by the USPTO and EPO.
Frequently Asked Questions
What is CPC class A61M?
How many patents have been filed in A61M?
Which company holds the most patents in A61M?
How is patent data for A61M collected?
What is the difference between CPC class and subclass?
Learn More
Explore the patent dataset
Read our methodology — how this data is sourced, computed, and verified.